Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in Stage I low-risk trophoblastic neoplasia

P. Cavoretto, C. Gentile, G. Mangili, E. Garavaglia, L. Valsecchi, D. Spagnolo, S. Montoli, M. Candiani

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: Methotrexate (MTX) resistance is defined on the basis of the human chorionic gonadotropin (hCG) curve. The aim of this study was to identify low-risk non-metastatic patients with gestational trophoblastic neoplasia (GTN) who can achieve resolution by continuing MTX treatment despite a transient hCG plateau. Methods: Before starting chemotherapy, 24 patients with FIGO Stage I GTN underwent transvaginal ultrasonography with power Doppler in order to identify myometrial lesions (areas of increased echogenicity and increased power Doppler signal). Ultrasound response to chemotherapy was defined when myometrial lesions decreased in echogenicity, Doppler signal or size. When ultrasound response occurred, despite chemoresistance defined by hCG values, MTX treatment was continued. Results: MTX was continued in three out of seven chemoresistant patients because ultrasound suggested response to MTX. All three of these patients achieved a complete response, thus nearly halving the MTX-resistance rate. Conclusion: Among patients who are candidates for second-line treatment on the basis of hCG, ultrasound may identify those in whom further MTX administration can induce a delayed complete response.

Original languageEnglish
Pages (from-to)99-105
Number of pages7
JournalUltrasound in Obstetrics and Gynecology
Volume40
Issue number1
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Drug Resistance
Methotrexate
Drug Therapy
Chorionic Gonadotropin
Neoplasms
Gestational Trophoblastic Disease
Ultrasonography
Therapeutics

Keywords

  • Doppler
  • gestational trophoblastic neoplasia
  • GTN
  • methotrexate
  • transvaginal ultrasound

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Reproductive Medicine
  • Medicine(all)

Cite this

Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in Stage I low-risk trophoblastic neoplasia. / Cavoretto, P.; Gentile, C.; Mangili, G.; Garavaglia, E.; Valsecchi, L.; Spagnolo, D.; Montoli, S.; Candiani, M.

In: Ultrasound in Obstetrics and Gynecology, Vol. 40, No. 1, 07.2012, p. 99-105.

Research output: Contribution to journalArticle

Cavoretto, P. ; Gentile, C. ; Mangili, G. ; Garavaglia, E. ; Valsecchi, L. ; Spagnolo, D. ; Montoli, S. ; Candiani, M. / Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in Stage I low-risk trophoblastic neoplasia. In: Ultrasound in Obstetrics and Gynecology. 2012 ; Vol. 40, No. 1. pp. 99-105.
@article{c246a8c7458b4cecb5cb4ed72beb8772,
title = "Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in Stage I low-risk trophoblastic neoplasia",
abstract = "Objectives: Methotrexate (MTX) resistance is defined on the basis of the human chorionic gonadotropin (hCG) curve. The aim of this study was to identify low-risk non-metastatic patients with gestational trophoblastic neoplasia (GTN) who can achieve resolution by continuing MTX treatment despite a transient hCG plateau. Methods: Before starting chemotherapy, 24 patients with FIGO Stage I GTN underwent transvaginal ultrasonography with power Doppler in order to identify myometrial lesions (areas of increased echogenicity and increased power Doppler signal). Ultrasound response to chemotherapy was defined when myometrial lesions decreased in echogenicity, Doppler signal or size. When ultrasound response occurred, despite chemoresistance defined by hCG values, MTX treatment was continued. Results: MTX was continued in three out of seven chemoresistant patients because ultrasound suggested response to MTX. All three of these patients achieved a complete response, thus nearly halving the MTX-resistance rate. Conclusion: Among patients who are candidates for second-line treatment on the basis of hCG, ultrasound may identify those in whom further MTX administration can induce a delayed complete response.",
keywords = "Doppler, gestational trophoblastic neoplasia, GTN, methotrexate, transvaginal ultrasound",
author = "P. Cavoretto and C. Gentile and G. Mangili and E. Garavaglia and L. Valsecchi and D. Spagnolo and S. Montoli and M. Candiani",
year = "2012",
month = "7",
doi = "10.1002/uog.11097",
language = "English",
volume = "40",
pages = "99--105",
journal = "Ultrasound in Obstetrics and Gynecology",
issn = "0960-7692",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in Stage I low-risk trophoblastic neoplasia

AU - Cavoretto, P.

AU - Gentile, C.

AU - Mangili, G.

AU - Garavaglia, E.

AU - Valsecchi, L.

AU - Spagnolo, D.

AU - Montoli, S.

AU - Candiani, M.

PY - 2012/7

Y1 - 2012/7

N2 - Objectives: Methotrexate (MTX) resistance is defined on the basis of the human chorionic gonadotropin (hCG) curve. The aim of this study was to identify low-risk non-metastatic patients with gestational trophoblastic neoplasia (GTN) who can achieve resolution by continuing MTX treatment despite a transient hCG plateau. Methods: Before starting chemotherapy, 24 patients with FIGO Stage I GTN underwent transvaginal ultrasonography with power Doppler in order to identify myometrial lesions (areas of increased echogenicity and increased power Doppler signal). Ultrasound response to chemotherapy was defined when myometrial lesions decreased in echogenicity, Doppler signal or size. When ultrasound response occurred, despite chemoresistance defined by hCG values, MTX treatment was continued. Results: MTX was continued in three out of seven chemoresistant patients because ultrasound suggested response to MTX. All three of these patients achieved a complete response, thus nearly halving the MTX-resistance rate. Conclusion: Among patients who are candidates for second-line treatment on the basis of hCG, ultrasound may identify those in whom further MTX administration can induce a delayed complete response.

AB - Objectives: Methotrexate (MTX) resistance is defined on the basis of the human chorionic gonadotropin (hCG) curve. The aim of this study was to identify low-risk non-metastatic patients with gestational trophoblastic neoplasia (GTN) who can achieve resolution by continuing MTX treatment despite a transient hCG plateau. Methods: Before starting chemotherapy, 24 patients with FIGO Stage I GTN underwent transvaginal ultrasonography with power Doppler in order to identify myometrial lesions (areas of increased echogenicity and increased power Doppler signal). Ultrasound response to chemotherapy was defined when myometrial lesions decreased in echogenicity, Doppler signal or size. When ultrasound response occurred, despite chemoresistance defined by hCG values, MTX treatment was continued. Results: MTX was continued in three out of seven chemoresistant patients because ultrasound suggested response to MTX. All three of these patients achieved a complete response, thus nearly halving the MTX-resistance rate. Conclusion: Among patients who are candidates for second-line treatment on the basis of hCG, ultrasound may identify those in whom further MTX administration can induce a delayed complete response.

KW - Doppler

KW - gestational trophoblastic neoplasia

KW - GTN

KW - methotrexate

KW - transvaginal ultrasound

UR - http://www.scopus.com/inward/record.url?scp=84863223286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863223286&partnerID=8YFLogxK

U2 - 10.1002/uog.11097

DO - 10.1002/uog.11097

M3 - Article

C2 - 22262502

AN - SCOPUS:84863223286

VL - 40

SP - 99

EP - 105

JO - Ultrasound in Obstetrics and Gynecology

JF - Ultrasound in Obstetrics and Gynecology

SN - 0960-7692

IS - 1

ER -